Xiaolin Zhang, Dizal CEO
#ESMO22: Dizal touts win in niche NSCLC population cornered by Takeda, J&J
AstraZeneca spinout Dizal said its cancer drug cleared the primary goal in a Phase II trial of patients with EGFR exon 20 insertion mutations, for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.